Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Documento de consenso-Reference-Cited by-同舟云学术

Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Documento de consenso

Published:2015-09 Issue:5 Volume:35 Page:421-447
ISSN:0211-6995
Container-title:Nefrología
language:es
Short-container-title:Nefrología

Author:

Campistol Josep M.,Arias Manuel,Ariceta Gema,Blasco Miguel,Espinosa Laura,Espinosa Mario,Grinyó Josep M.,Macía Manuel,Mendizábal Santiago,Praga Manuel,Román Elena,Torra Roser,Valdés Francisco,Vilalta Ramón,Rodríguez de Córdoba Santiago

Publisher

Elsevier BV

Subject

Nephrology

Reference149 articles.

1. Atypical hemolytic uremic syndrome;Loirat;Orphanet J Rare Dis,2011

2. Management of hemolytic uremic syndrome;Loirat;Presse Med,2012

3. Alexion Pharmaceuticals I. Soliris (eculizumab). Ficha técnica 2012.

4. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria;Rother;Nat Biotechnol,2007

5. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome;Legendre;N Engl J Med,2013

Cited by 149 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. [Translated article] Pharmacokinetics of eculizumab in adult and pediatric patients with atypical hemolytic uremic syndrome and C3 glomerulopathy;Farmacia Hospitalaria;2024-01

2. Farmacocinética de eculizumab en pacientes adultos y pediátricos con síndrome hemolítico urémico atípico y glomerulopatía C3;Farmacia Hospitalaria;2024-01

3. Eculizumab in Shiga toxin-producing Escherichia coli hemolytic uremic syndrome: a systematic review;Pediatric Nephrology;2023-12-06

4. Recommendations for the individualised management of atypical hemolytic uremic syndrome in adults;Frontiers in Medicine;2023-12-01

5. Endothelial activation and damage as a common pathological substrate in different pathologies and cell therapy complications;Frontiers in Medicine;2023-11-14